Serous Adenocarcinoma — Trials

Serous Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 85
Recruiting: 35
Ph III recruiting: 6
Growth YoY: —
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (24)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07832227	Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial(SIERRA)	not yet recruiting	Phase 2	60	Dana-Farber Cancer InstituteOTHER	0	Sep 21, 2026	clinicaltrials
NCT07747506	Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)	not yet recruiting	Phase 2	2	Verastem, Inc.INDUSTRY	1	Aug 5, 2026	clinicaltrials